Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than with Ibrutinib Alone or FCR Regimen Among Patients with CLL By Ogkologos - October 13, 2025 346 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FLAIR study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Patient Guide in Hepatocellular Carcinoma Now Available Also in German December 16, 2025 How a Musician Copes With Life With Metastatic Breast Cancer March 17, 2021 EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... June 28, 2024 Robin Williams Required Film Companies He Worked With To Hire Homeless... November 25, 2021 Load more HOT NEWS UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation Targeting CLDN18.2 with Zolbetuximab Prolongs Survival When Combined with mFOLFOX6 in... Fears breast cancer progress could stall due to COVID-19 backlog FDA Approves Belzutifan for Cancers Associated with Von Hippel-Lindau Disease
